|
Regeneron speeds toward the FDA with its would-be asthma blockbuster
FierceBiotech Meanwhile, after meeting with the FDA, Regeneron now believes the agency will recognize an earlier Phase IIb asthma study as one of two required pivotal trials. In that trial, the highest doses of dupilumab significantly beat out placebo in improving … Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in … |
View full post on asthma – Google News